Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.

× No keyword cloud information.

23 in total

1. Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins?

Authors: James K Liao
Journal: Circulation Date: 2011-04-25 Impact factor: 29.690

2. Statins in combinations: from ARBITER-6 HALTS to ACCORD--what works?

Authors: Michael Clearfield
Journal: Curr Atheroscler Rep Date: 2011-02 Impact factor: 5.113

Review 3. Therapies targeting exogenous cholesterol uptake: new insights and controversies.

Authors: Michael H Davidson
Journal: Curr Atheroscler Rep Date: 2011-02 Impact factor: 5.113

4. Clinical Efficacy and Tolerability of Ezetimibe in Combination With Atorvastatin in Japanese Patients With Hypercholesterolemia-Ezetimibe Phase IV Randomized Controlled Trial in Patients With Hypercholesterolemia.

Authors: Tamio Teramoto; Teruo Sawada; Kazuya Iwamoto; Hiroyuki Daida
Journal: Curr Ther Res Clin Exp Date: 2012-02

Review 5. Testing cardiovascular drug safety and efficacy in randomized trials.

Authors: Garret A FitzGerald
Journal: Circ Res Date: 2014-03-28 Impact factor: 17.367

6. Medication Discontinuation in the IMPROVE-IT Trial.

Authors: Ann Marie Navar; Matthew T Roe; Jennifer A White; Christopher P Cannon; Yuliya Lokhnygina; L Kristin Newby; Robert P Giugliano; Andrew M Tershakovec; Eugene Braunwald; Robert M Califf; Michael A Blazing
Journal: Circ Cardiovasc Qual Outcomes Date: 2019-01

Review 7. Beyond statins: new lipid lowering strategies to reduce cardiovascular risk.

Authors: Davide Noto; Angelo B Cefalù; Maurizio R Averna
Journal: Curr Atheroscler Rep Date: 2014-06 Impact factor: 5.113

8. Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency.

Authors: Margus Viigimaa; Helena Vaverkova; Michel Farnier; Maurizio Averna; Luc Missault; Mary E Hanson; Qian Dong; Arvind Shah; Philippe Brudi
Journal: Lipids Health Dis Date: 2010-11-04 Impact factor: 3.876

9. Niacin or ezetimibe for patients with, or at risk of coronary heart disease.

Authors: Robert Guthrie
Journal: Clin Med Insights Cardiol Date: 2010-10-31

Review 10. Origin and therapy for hypertriglyceridaemia in type 2 diabetes.

Authors: Jing Pang; Dick C Chan; Gerald F Watts
Journal: World J Diabetes Date: 2014-04-15